Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (April 2019)
20 slides from Hemostemix's investor presentation, Apr 1, 2019
Slide 1: The Future of Healthcare Is Regenerative Medicine
THE FUTURE OF HEALTHCARE IS REGENERATIVE MEDICINE APRIL 01, 2019
Slide 2: Forward-Looking Information
2 F O RWA R D - L O O K I N G I N F O R M AT I O N This presentation contains forward looking statements that reflect management’s expectations regarding the future growth, results of operations, performance (both operational and financial) and business prospects and opportunities of Hemostemix Inc.
Slide 3: Hemostemix Inc. Blood Derived Stem Cell Therapies
3 HEMOSTEMIX INC. BLOOD DERIVED STEM CELL THERAPIES Hemostemix Inc. (TSXV:HEM; OTCQB:HMTXF) A Canadian public biotechnology The Company has a robust IP portfolio of Its lead product, ACP-01 is currently at company focused on the research, over 50 patents issued and pending for its midpoint of a US F
Slide 4: Hemostemix at a Glance
4 H E M O S T E M I X – AT A G L A N C E Safe & Effective Key Partnerships • 50+ Patents issued or • Manufacturing Agreement in place with pending worldwide FDA approved cGMP (Certified Good • Unique Processes Manufacturing Practice) facility • Low Risk Safety & Efficacy • Licensing Agreement in pla
Slide 5: The Importance of Stem Cell Therapy
5 T H E I M P O R TA N C E O F STEM CELL THERAPY Strong Government Population and Disease Trends and Public support Lifestyle Factors • CLI is a major global health • Regenerative medicine is leading • Aging populations worldwide, problem - incidence growing with edge for biotech investment especial
Slide 6: Technology Differentiators
6 T E C H N O L O G Y D I F F E R E N T I ATO R S Proven safety and efficacy in >300 Blood draw, safer and less Strong IP portfolio of 50+ patents historical patients treated with ACP-01 invasive than bone marrow Safe & Effective Non-surgical, enhanced cell therapy treatment for restoring circulatio
Slide 7: Potential Markets
7 POTENTIAL MARKETS Tip of the Iceberg Critical Limb Ischemia CLI - Estimated total costs up to & Buerger’s Disease $248B¹ in US. Ischemic Dilated Cardiomyopathy Cardiovascular Disease Congestive Heart Failure (CVD) In the United States, total Acute Myocardial Infarction costs of CVD in 2016 was $55
Slide 8: About Critical Limb Ischemia (CLI)
8 ABOUT CRITICAL LIMB ISCHEMIA (CLI) Critical limb ischemia is a chronic condition and is the most severe and deadliest form of peripheral arterial disease (PAD) with limited treatment options. CLI is characterized by insufficient blood supply to lower limbs. Complications include leg and foot ulcer
Slide 9: ACP-01 for Critical Limb Ischemia
9 ACP-01 FOR CRITICAL LIMB ISCHEMIA Hope for CLI Patients Facing Amputation 01 02 Extract and enrich desired Inject cell population cell population from to form new blood vessels patient’s blood in dying tissue Self-Donor Simple Quick Uses patient’s own cells, Cell harvest via blood draw 7 days from
Slide 10: CLI and the ACP-01 Benefit - The Visualization
10 C L I A N D T H E A C P - 0 1 B E N E F I T- T H E V I SU A L I Z AT I O N 47 Days post ACP-01 Treatment Before After © 2019 HEMOSTEMIX INC. ALL RIGHTS RESERVED. | OTCQB:HMTXF – TSX VENTURE:HEM
Slide 11: Phase II Clinical Trial for CLI
11 PHASE II CLINICAL TRIAL FOR CLI Randomized, placebo-controlled double blind Phase II clinical trial to confirm the safety and efficacy of ACP-01 US FDA and Health Canada approved protocol for trial Phase II Trial well under way Minimum 6 month up to 12 CRO engaged month follow-up US and Canada Ex
Slide 12: Phase II CLI Clinical Trial Milestones
12 PHASE II CLI CLINICAL T R I A L M I L E S TO N E S H2 2017 H1 2018 H2 2018 H1 2019 H2 2019 H1 2020 H2 2020 Phase II CLI Trial CRO engaged Health Canada Approval¹ US FDA Approval² Site & Patient Recruiting⁴ First Patient Treatment³ Patient Monitoring⁴ Interim Data⁴ Study Completion⁴ A catalyst for
Slide 13: Study and Trial History
13 S T U D Y A N D T R I A L H I S TO RY Current Phase II Clinical Trial for CLI in progress in Canada and the USA Study Number of Type of Study Study Location Objective of Study Patients Study Status Design Subjects Pilot Safety/ To assess the feasibility and safety Thailand Open label 6 Diagnosed
Slide 14: Product Pipeline
14 PRODUCT PIPELINE Robust pipeline and path towards other trials and commercialization Development Phase Candidate Indication Status Preclinical Clinical • Trial site and patient ACP-01 • Critical limb ischemia • Phase II clinical trial enrollment In progress • Congestive Heart Disease • Preparing
Slide 15: Directors and Management Team
15 D I R E C TO R S A N D M A N A G E M E N T T E A M Proven management team with extensive business, public company, R&D, and scientific trial experience Angus Jenkins Donald Friesen David L. Wood Chairman Board of Directors Kyle Makofka Dr. Alan J. Jacobs Kristin Gulka Chief Executive Officer MSEE
Slide 16: Management and Board of Directors
16 Dr. Alan J. Jacobs, MSEE, MD, PhD, President / CMO MANAGEMENT • Former founder, president and chief medical officer of several biotech companies • Clinical development resulting in two licensing transactions with big pharma Kristin Gulka, CFO • Over 20 years of experience developing, manufacturin
Slide 17: Scientific Leadership Team and Scientific Advisory Board
17 SCIENTIFIC LEADERSHIP TEAM Dr. Alan J. Jacobs, MSEE, MD, PhD, Chief Medical Officer Catherine St. George, B.Sc., C.C.R.P. Clinical Trial Manager • Former founder, president and chief medical officer of several biotech companies • Over 20 years of clinical research experience in phase II and III d
Slide 18: Share Capital Overview
18 S H A R E C A P I TA L O V E RV I E W Share capital structure as of December 31, 2018 (Canadian dollars) Number Ex. Price Expiry Common Shares Issued and outstanding 300,898,610 Stock Options 29,417,230 $0.05-$0.10 Jan 2019-Sept 2023 Share Purchase Warrants² 114,818,564 $0.05-$0.65 Sept 2019-Dec
Slide 19: 2019: Poised for Growth
19 2019: POISED FOR GROWTH CLI phase II clinical trial enrolling sites and patients Autologous and allogeneic process for ACP-01 Fully expandable platform designed for commercialization Robust R&D pipeline Recent manufacturing refinements to reduce ACP-01 Phase I angina trial complete – planning pha
Slide 20: Contact Information
20 C O N TA C T I N F O R M AT I O N Hemostemix Inc. Suite 2150, 300-5th Avenue SW Calgary, AB T2P 3C4 www.hemostemix.com For more Information please contact: Shaping Kyle Makofka The Future CEO of Medicine [email protected] 403-506-3373 © 2019 HEMOSTEMIX INC. ALL RIGHTS RESERVED. | OTCQB:HMTX